Singapore markets open in 2 hours 12 minutes

NLS Pharmaceutics AG (NLSP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4750-0.0250 (-1.67%)
At close: 03:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 55.29M
Enterprise value 54.29M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)25.78
Enterprise value/revenue N/A
Enterprise value/EBITDA -3.40

Trading information

Stock price history

Beta (5Y monthly) -0.84
52-week change 319.52%
S&P500 52-week change 3-12.21%
52-week high 31.8800
52-week low 30.3300
50-day moving average 31.4750
200-day moving average 30.8735

Share statistics

Avg vol (3-month) 389.96k
Avg vol (10-day) 374.82k
Shares outstanding 535.67M
Implied shares outstanding 6N/A
Float 89.51M
% held by insiders 127.14%
% held by institutions 118.17%
Shares short (27 Feb 2023) 4143.49k
Short ratio (27 Feb 2023) 43.48
Short % of float (27 Feb 2023) 40.48%
Short % of shares outstanding (27 Feb 2023) 40.40%
Shares short (prior month 30 Jan 2023) 4119.8k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-193.74%
Return on equity (ttm)-15,407.31%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -16M
Net income avi to common (ttm)-15.98M
Diluted EPS (ttm)-1.1100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.35M
Total cash per share (mrq)0.08
Total debt (mrq)354.34k
Total debt/equity (mrq)N/A
Current ratio (mrq)0.59
Book value per share (mrq)-0.23

Cash flow statement

Operating cash flow (ttm)-12.87M
Levered free cash flow (ttm)-7.66M